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Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus disease 2019 (COVID-19),
has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed
to SARS–CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., “convalescent”) plasma refers to plasma
that is collected from individuals following resolution of infection and development of antibodies. Passive antibody
administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate
immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used
successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of
coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in
the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in
viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and
constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced
challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself.
Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its
use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid
disease). We provide […]
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Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the 
cause of coronavirus disease 2019 (COVID-19), has been declared a 
pandemic (1). As of the time of this writing, over 1.2 million cases of 
COVID-19 have been reported, spanning 181 countries or regions and 
contributing to over 64,000 deaths (2). Despite a global health crisis 
that is unparalleled in modern history, there are currently no proven 
options for prophylaxis for those who have been exposed to SARS–
CoV-2 nor is there therapy for those who go on to develop COVID-19.
Immune (i.e. “convalescent”) plasma refers to plasma that is 
collected from individuals following resolution of infection and 
development of antibodies. Passive antibody therapy, through 
transfusion of convalescent plasma, may prevent clinical infec-
tion or blunt clinical severity in individuals with recent pathogen 
exposure. Antibody therapy can also be used to treat patients who 
are already manifesting symptoms of varying severity. However, 
passive antibody therapy is most effective when administered pro-
phylactically or used early after the onset of symptoms (3, 4).
Passive antibody therapy has been in use for over a century 
(5). The active agents are antibodies against the target pathogen of 
interest. Today, passive antibody therapy relies primarily on pooled 
immunoglobulin preparations that contain high concentrations of 
antibodies. In contrast, plasma has been used emergently in epi-
demics where there is insufficient time or resources to generate 
immunoglobulin preparations. There are multiple examples, both 
historical and recent, in which convalescent plasma was employed 
successfully as postexposure prophylaxis (e.g., hepatitis, mumps, 
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus disease 2019 (COVID-19), has 
spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to 
SARS–CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., “convalescent”) plasma refers to plasma that is 
collected from individuals following resolution of infection and development of antibodies. Passive antibody administration 
through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity 
to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as 
postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, 
Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited 
data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. 
Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent 
plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning 
donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of 
convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., 
prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent 
plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-
up is brought underway to mobilize this critical resource.
Deployment of convalescent plasma for the prevention 
and treatment of COVID-19
Evan M. Bloch,1 Shmuel Shoham,2 Arturo Casadevall,3 Bruce S. Sachais,4 Beth Shaz,4 Jeffrey L. Winters,5 Camille van Buskirk,5 
Brenda J. Grossman,6 Michael Joyner,7 Jeffrey P. Henderson,8,9 Andrew Pekosz,3 Bryan Lau,10 Amy Wesolowski,10 Louis Katz,11  
Hua Shan,12 Paul G. Auwaerter,2 David Thomas,2 David J. Sullivan,3 Nigel Paneth,13,14 Eric Gehrie,1 Steven Spitalnik,15  
Eldad A. Hod,15 Lewis Pollack,16 Wayne T. Nicholson,7 Liise-anne Pirofski,17 Jeffrey A. Bailey,18 and Aaron A.R. Tobian1
1Division of Transfusion Medicine, Department of Pathology, 2Department of Infectious Diseases, School of Medicine, and 3Department of Molecular Microbiology and Immunology, Bloomberg School of 
Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 4New York Blood Center Enterprises, New York, New York, USA. 5Division of Transfusion Medicine, Department of Laboratory Medicine 
and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 6Department of Pathology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. 7Department of Anesthesiology and 
Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. 8Department of Medicine and 9Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, 
Missouri, USA. 10Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 11Mississippi Valley Regional Blood Center, Davenport, Iowa, USA. 
12Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA. 13Department of Epidemiology and Biostatistics and 14Department of Pediatrics and Human Development, 
Michigan State University, East Lansing, Michigan, USA. 15Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York–Presbyterian Hospital, New York, New York, USA. 
16Independent consultant, Princeton, New Jersey. 17Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA. 18Department of Pathology 
and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Conflict of interest: EMB is a member of the FDA Blood Products Advisory Committee.
Copyright: © 2020, American Society for Clinical Investigation.
Reference information: J Clin Invest. 2020;130(6):2757–2765.  
https://doi.org/10.1172/JCI138745.
The Journal of Clinical Investigation R E V I E W
2 7 5 8 jci.org   Volume 130   Number 6   June 2020
able viral loads. Further, screening of 39 of 40 (97.5%) of recov-
ered COVID-19 patients displayed neutralizing antibody titers 
for 160 or more. A case series of five critically ill patents in China 
also reported improvement in clinical status following transfu-
sion with convalescent plasma (SARS–CoV-2 IgG titers >1000), 
as evidenced by weaning off mechanical ventilation, reduction 
in viral loads, improved oxygenation, and clinical stabilization 
(21). Although constrained by small sample sizes and limitations 
of study design and concomitant treatment modalities (e.g., rem-
desivir, ribavirin, corticosteroids, etc.), these findings suggest that 
administration of convalescent plasma is safe, reduces viral load, 
and may improve clinical outcomes. This has led to calls for the 
wider adoption of convalescent plasma for COVID-19 (23). None-
theless, while the data support safety and potential efficacy of con-
valescent plasma, randomized trials are needed (23). Similarly, 
high-dose intravenous immunoglobulin (IVIg) has been suggest-
ed as a potential therapy for COVID-19 (24); however, supporting 
data are few and marred by potential confounders.
Regulatory oversight and access to convalescent 
plasma
On March 24, 2020, the US FDA published its guidance document 
for investigational COVID-19 convalescent plasma (25). The doc-
ument outlines three pathways for access to convalescent plasma. 
The first is under an emergency use investigational new drug (IND) 
application. This allows a provider to apply for compassionate use 
in an individual patient with severe or immediately life-threaten-
ing COVID-19. Of note, this guidance document does not allow 
for prophylaxis. Minimal requirements (e.g., a brief history and 
description of indication) enable those requests to be expedited. 
The second is a traditional pathway to apply for an IND to support 
research (e.g., for clinical trials). Finally, a government-led initia-
tive provides expanded access of convalescent plasma to partic-
ipating institutions under a master treatment protocol. The latter 
approach enables the collection of extensive data, albeit through a 
nonrandomized study design.
Convalescent plasma collections workflow
Convalescent plasma can be mobilized rapidly using the estab-
lished blood collection and transfusion infrastructure. Specifically, 
convalescent plasma is obtained and administered using standard 
collection and transfusion practices that are available around the 
world. As the number of individuals who resolve their infections 
increases, so does the number of potential eligible donors of con-
valescent plasma. Nonetheless, there are multiple logistical hur-
dles if we are to procure a satisfactory inventory of convalescent 
plasma. As depicted in Figure 1, a workflow has been developed to 
illustrate the individual steps that need to be undertaken spanning 
assessment of donor eligibility, donor recruitment, collections, 
and transfusion itself. Each brings its own challenges.
Donor eligibility. First is the question of what constitutes a 
convalescent donor. Relying only on absence of symptoms invites 
test-seeking behavior that could overwhelm — or at least burden 
unnecessarily — collection services with inappropriate donors. 
The criteria for individuals to be eligible to donate convalescent 
plasma include a history of COVID-19, either as confirmed by 
approved molecular testing (e.g., nasopharyngeal [NP] swab) or 
polio, measles, rabies) and/or treatment for a myriad of infectious 
diseases (e.g., influenza, Argentine hemorrhagic fever, SARS-
CoV, Middle East respiratory syndrome [MERS], Ebola), favorably 
affecting a range of laboratory (e.g., viral loads, cytokine respons-
es) and clinical outcomes (notably mortality) (6–12).
Mechanism of action
The antibodies present in immune (i.e., convalescent”) plasma 
mediate their therapeutic effect through a variety of mechanisms. 
An antibody can bind to a given pathogen (e.g., virus), thereby 
neutralizing its infectivity directly, while other antibody-mediated 
pathways, such as complement activation, antibody-dependent 
cellular cytotoxicity, and/or phagocytosis, may also contribute 
to its therapeutic effect. Nonneutralizing antibodies that bind to 
the pathogen — but do not interfere with its ability to replicate 
in in vitro systems — may also contribute to prophylaxis and/or 
enhance recovery (13, 14). Importantly, passive antibody admin-
istration offers the only short-term strategy for conferring imme-
diate immunity to susceptible individuals. This is particularly the 
case in the setting of a novel, emerging infectious disease such 
as SARS–CoV-2/COVID-19. While fractionated plasma products 
(e.g., hyperimmune globulin, mAbs) and/or vaccination may offer 
durable therapeutic options, human anti–SARS–CoV-2 plasma is 
the only therapeutic strategy that is immediately available for use 
to prevent and treat COVID-19.
The use of convalescent plasma against 
coronaviruses
Convalescent plasma has been used in two other coronavirus epi-
demics in the 21st century: SARS1 in 2003 and MERS from 2012 
to the present. Experience from those outbreaks shows that con-
valescent plasma contains neutralizing antibodies (15). The larg-
est study involved the treatment of 80 patients in Hong Kong with 
SARS1 (16). Compared with those given plasma later, patients who 
were treated before day 14 had improved outcomes, as defined by 
discharge from hospital before day 22, supporting early adminis-
tration for optimal effect. Limited data also suggested benefit in 
seriously ill individuals: three patients with SARS–CoV-1 infec-
tion in Taiwan were treated with convalescent plasma, result-
ing in a reduction in viral load; all three recipients survived (17). 
Treatment with convalescent plasma was also reported in three 
patients in South Korea with MERS (18). Treatment using conva-
lescent plasma in patients with MERS was limited by a small pool 
of donors with sufficient antibody levels (19). Reported dosages 
and characterization of convalescent plasma (i.e., with respect to 
antibody titers) is highly variable (Table 1).
In this current pandemic, there are reports that convalescent 
plasma has been used in China to treat patients with COVID-19 
(20, 21). In a pilot study of 10 patients with severe COVID-19, 
the investigators collected convalescent plasma with neutralizing 
antibody titers at or exceeding a 1:640 dilution (22). Transfusion 
of convalescent plasma resulted in no serious adverse effects in 
the recipients. All 10 patients had improvement in symptoms (e.g., 
fever, cough, shortness of breath, and chest pain) within 1 to 3 days 
of transfusion; they also demonstrated radiological improvement 
in pulmonary lesions. In seven RNA-emic patients, transfusion of 
convalescent plasma was temporally associated with undetect-
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severe blood shortages given canceled blood drives, blood cen-
ters have been forced to prioritize their efforts accordingly, while 
still planning for convalescent plasma collection. The latter pres-
ents an additional burden on the blood centers, particularly while 
contending with the logistical constraints posed by COVID-19 
(e.g., limited staffing, a contracted donor pool, travel restrictions, 
etc.). Of note, while convalescent plasma could compete with rou-
tine plasma collections, this may be offset by lowered demand for 
standard plasma, given COVID-19 mitigation measures, such as 
canceled elective surgeries.
Predonation screening to qualify convalescent donors. There is 
still uncertainty surrounding the optimal workflow for predona-
tion screening. Heterogeneity in approaches based on local capac-
ity and needs is expected. We have proposed a two-step process 
that divorces the blood center from the predonation screening; 
the predonation screening is left to the clinical provider, who per-
forms an assessment of the donor, collects an NP swab for nucleic 
acid testing to confirm that the individual is virus free (i.e., in the 
event that a negative test has not yet been obtained), and collects 
a blood sample for antibody testing before referring the donor 
the presence of antibodies against SARS-CoV-2 and at least 14 
days passing after the resolution of symptoms (e.g., fever, cough, 
shortness of breath). 
Donor recruitment. Those who have recovered from COVID-19 
will be recruited to serve as potential blood donors. Given the 
magnitude of the pandemic, finding donors is not anticipated to 
be a problem. Approaches include community outreach in areas 
with robust epidemics, advertising, and communication through 
media, and/or directly through providers (e.g., at time of dis-
charge) and their professional organizations (e.g., databases, 
websites — http://ccpp19.org). There is also consideration about 
messaging those who receive positive results either prospectively 
or after the fact. The latter poses some ethical concerns, which 
weigh public health need against patient privacy and confidenti-
ality. A limited waiver of HIPAA in the US may allow for greater 
freedom in this regard (26). Blood centers have well-developed 
infrastructure for donor recruitment; while they may be best 
equipped to oversee recruitment in collaboration with partner 
hospitals, their primary responsibility is to ensure an adequate 
blood supply to meet clinical demand. Confronted with recent, 
Table 1. Dosing of convalescent plasma in coronavirus epidemics
Disease Location Dose of CP Titer Summary finding Reference
SARS1 Hong Kong, China Mean volume 279.3 ±  
127.1 mL(range,  
160–640 mL)
Not performed - Retrospective chart review of 80 patients who received CP
- ~14 (range, 7–30 days) following the onset of symptoms
- Good clinical outcome in 33 (41.3%) patients as defined by  
 hospital discharge by day 22
- Improved outcome associated with early administration
- No adverse events
16
SARS1 Taipei, Taiwan 500 mL Serum antibody (IgG) titer was >640 - Uncontrolled case series of 3 severely ill patients
- Improvement in clinical status of all 3 patients
17
SARS1 Hong Kong, China 200 mL Not stated - Case report of one patient
- Improved clinical status
- Other therapies also used
- No adverse effect
52
SARS1 Shenzhen, China 2 units of 250 mL each 
(total 500 mL);  
transfused 12 hours apart 
Not stated - Letter to editor/case report of one patient
- Improvement in clinical status
53
MERS Seoul, South Korea 4 transfusions of CP to  
3 patients; volumes  
not stated
PRNT negative (n = 2), 1:40 (n = 1)  
and 1:80 (n = 1)
- Uncertain benefit, although all 3 patients survived
- ELISA IgG optical density of 1.9 predictive of PRNT titer ≥1:80  
 with 100% specificity
18
MERS Riyadh, Saudi Arabia 2 units (250–350  
mL/unit) proposed  
for phase 2
- Of 196 individuals with suspected or  
 confirmed MERS-CoV: 8 (2.7%) reactive  
 by ELISA; 6 of 8 reactive by MN. 
- Of 230 exposed healthcare workers: 4  
 (1.7%) reactive by ELISA; 3 of 4 reactive  
 by MN.
- Feasibility study to assess proportion of convalescent donors  
 that had antibodies against MERS-CoV
- No transfusions of CP undertaken
19
MERS Seoul, South Korea 250 mL Not stated - Case report (letter to editor) of 1 patient
- Possible TRALI reported
54
COVID-19 Wuhan, China 200 mL Neutralizing anti-SARS-CoV-2–antibody  
titer >1:640
- Uncontrolled case series of 10 severely ill patients
- Other therapies included steroids, antimicrobials, antivirals
- Median onset of symptoms to CP 16.5 days (IQR 11.0–19.3 days)
- Improvement in clinical status of all patients
- No significant adverse effect
22
COVID-19 Shenzhen, China 2 consecutive transfusions 
of 200–250 mL (400 mL 
total)
- ELISA anti-SARS–CoV-2–antibody  
 titer >1:1000
- Neutralizing antibody titer >40
- Uncontrolled case series of 5 critically ill patients
- Administration of CP 10–22 days after admission
- All had had steroids and antivirals
- Improvement in clinical status of all patients
21
CP, convalescent plasma; PRNT, plaque reduction neutralization assay; MN, microneutralization assay.
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(e.g., ELISA) are available, but commercially available assays have 
not been rigorously validated. Further, the relationship between 
total anti–SARS–CoV-2 antibodies and neutralizing anti–SARS–
CoV-2 antibodies remains unclear. There is also uncertainty as 
to whether total antibodies or subclasses (e.g., IgM, IgG, or IgA) 
are the optimal measure and which antigen is most informative; 
in this regard, various forms of the spike or S protein have been 
tested and used (27, 28).
Limited data are currently available on the ELISAs. One group 
reported findings demonstrating both “strong reactivity against 
IgG3, IgM, and IgA” using assays targeting spike antigens and 
low crossreactivity when testing other human coronaviruses (27). 
Another group reported on performance of a point-of-care anti-
body test for combined detection of IgM and IgG, demonstrating 
a sensitivity and specificity of 88.7% and 90.6%, respectively (29).
The antibody titer will be affected by the timing of collection 
relative to onset of infection. While data are limited, seroconver-
sion has been observed to occur between 8 and 21 days after the 
onset of symptoms (28, 30). Coupled with reports from China of 
high titers of anti–SARS–CoV-2 antibodies in the overwhelming 
majority of convalescent patients, the findings suggest that units 
to a collection facility. Anti–SARS–CoV-2 provides evidence of 
resolved infection. Nonetheless, the original FDA guidance doc-
ument mandated evidence of a negative molecular test to ensure 
a reasonable measure of caution. This recommendation reflects 
the overriding mandate to protect safety given the current state of 
knowledge, which associates the presence of SARS–CoV-2 RNA in 
NP specimens with potential infectivity. The eligibility criteria for 
donation of convalescent plasma have evolved, rapidly. For one, 
the presence of antibodies against SARS-CoV-2 is now permissible 
as evidence of prior COVID-19. For another, the requirement for a 
negative test (e.g., NP swab) in those 14 to 27 days following reso-
lution of symptoms has since been relaxed.
Antibody testing. Antibody testing comes with its own challeng-
es, as reflected in the FDA guidance document. In general, one 
cannot qualify donors or manufacture a therapeutic agent using 
tests that have not been vetted appropriately. However, there is 
uncertainty as to which antibodies are optimally effective in the 
context of COVID-19. Neutralizing antibodies are likely to cor-
relate better with function. However, neutralizing antibody assays 
are not amenable to high-throughput screening in clinical labora-
tories and are not widely available. In contrast, quantitative assays 
Figure 1. Convalescent plasma collections workflow. EUA, Emergency Use Authorization; TTI, transfusion-transmitted infection.
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patients under emergency IND. Nonetheless, if institutions are 
left to recruit their own donors to support internal needs (i.e., for 
emergent use for individual patients), it raises the question of 
whether the blood centers have the ability to allocate units equi-
tably. Many hospitals lack the experience and capacity to recruit 
donors, limiting their access to the supply of convalescent plas-
ma. This model could also prove inefficient should donors pass 
predonation screening at the clinical provider, yet later fail qual-
ification upon presentation to the blood center. Once adequate 
donors are recruited and high-throughput testing is available, the 
model will likely change.
Proposed under the FDA’s expanded access program would 
be to regionalize or centralize recruitment, collections, and 
inventory management. Nonetheless, major obstacles remain 
with extant acuity of need and little time to construct an inven-
tory as proposed.
Optimal dosing and transfusion. Historically, the dosing of con-
valescent plasma has been highly variable, which may be ascribed 
to differences by indication (i.e., prevention versus treatment). 
Pertinent to the current pandemic, a study in China employed a 
single (200 mL) unit of plasma (22). In the planned clinical trials, 
one unit has been proposed for use for postexposure prophylaxis 
and one to two units have been proposed for treatment. The anti-
bodies’ duration of efficacy is unknown, but is postulated to last 
weeks to a few months (7, 31). The selected dosing was based on 
experience with previous use of convalescent plasma therapy in 
SARS, where 5 mL/kg of plasma at a titer of 1:160 or greater was 
utilized (16). Historically, prophylactic doses (in some cases only 
a quarter of that of the proposed treatment dose) have been used 
successfully. This was considered when designing the clinical tri-
als. Considering first-order linear proportionality, 3.125 mL/kg of 
plasma with a titer of greater than 1:64 would provide an equiva-
lent immunoglobulin level to one-quarter of 5 mL/kg plasma with 
a titer of 1:160 or greater.
For a typical patient (~80 kg), this would result in 250 mL of 
plasma (3.125 mL/kg × 80 kg = 250 mL > 1:64), approximating 
the volume of a standard unit of plasma in the US. This scheme 
imparts logistical ease to product preparation for adult transfu-
sions. In pediatric transfusions (trials are being planned), there 
will be the need to aliquot large volume units and dose by body 
weight. Given the current level of uncertainty, more precise mod-
els to estimate bioavailability in tissues where virus and host inter-
act are not yet possible.
Clinical trials to evaluate the safety and efficacy 
of human anti–SARS–CoV-2 plasma
Despite a favorable historical record, few controlled trials have 
been performed to evaluate the efficacy of convalescent plasma, 
in large part due to its emergency application in times of epidem-
ics. At least five clinical trials have been proposed to evaluate 
human anti–SARS–CoV-2 plasma for the prevention and treat-
ment of COVID-19.
The first trial is of the use of human anti–SARS–CoV-2 plasma 
as post-exposure prophylaxis: a randomized, blinded phase 2 trial 
will be undertaken to compare the efficacy and safety of human 
anti–SARS–CoV-2 plasma versus control (SARS–CoV-2 nonim-
mune plasma) among adults (age ≥ 18 years) who have had close 
of plasma that are collected 14 days or more after resolution of 
symptoms should contain high titers of antibodies (22). In the 
setting of a temporizing therapy, one needs to balance acuity of 
need with a desire for a highly validated assay and a refined treat-
ment modality. Indeed, the FDA guidance document manages 
this uncertainty by suggesting, rather than requiring testing, i.e., 
“defined SARS–CoV-2 neutralizing antibody titers, if testing can 
be conducted (e.g., optimally greater than or equal to 1:160)” 
(25). This will certainly change as antibody testing becomes more 
widely available. One could even foresee routine serosurveillance 
of blood donors, which would bypass the need for predonation 
screening, particularly if the convalescent plasma is produced 
from whole blood collections.
Collection and testing. Donors who have successfully complet-
ed predonation screening are directed to the blood center. We 
have developed a specialized form to alert the blood center of a 
convalescent plasma donor; the form confirms that all prescreen-
ing criteria have been met and that the plasma will be adminis-
tered under IND. This ensures that donors have largely been 
vetted prior to collection. Upon presentation to the blood center, 
donors still need to qualify as community volunteer blood donors 
through completion of a donor history questionnaire and standard 
physical examination as specified by FDA and professional stan-
dards of practice. It is recommended that common deferrals be 
ruled out during predonation screening (e.g., through administra-
tion of the questionnaire) to minimize on-site deferral at the blood 
center for reasons that would otherwise disqualify the individu-
als from community donation (e.g., risk factors for transfusion- 
transmissible infections).
Apheresis (rather than whole blood donation) is recommend-
ed to optimize the yield of convalescent plasma. Apheresis refers 
to an automated technology in which whole blood is continuous-
ly centrifuged into its components (i.e., red blood cells, plasma, 
platelets); this allows for selective collection of the desired blood 
fraction with return of the other components to the donor. This is 
highly efficient: approximately 400 to 800 mL of plasma can be 
obtained from a single apheresis donation, which then provides 
2 to 4 units of convalescent plasma for transfusion. The units are 
frozen within 24 hours of collection and quarantined — as is rou-
tine — pending results from standard blood donor testing. The 
latter fulfills regulatory requirements and mostly comprises test-
ing for transfusion-transmissible infections (e.g., HIV, hepatitis B 
and C viruses, etc.). There is also required testing of female donors 
with a history of pregnancy for HLA antibodies to mitigate the risk 
of transfusion-related acute lung injury (TRALI).
Distribution of convalescent plasma. In the traditional model of 
blood collections in the US and other high-income countries, the 
blood center recruits its own voluntary nonrenumerated blood 
donors, after which there is equitable distribution based on need. 
The distribution model in COVID-19 employs convalescent indi-
viduals as “directed donors.” The term directed donor typically 
refers to a friend or family member who donates specifically for a 
given patient. Directed donation is not actively encouraged, giv-
en that social pressure may disincentivize the donor’s admission 
of high-risk behavior. In contrast, the COVID-19 model employs 
the process differently, directing units to institutions (i.e., hos-
pitals) — rather than to individual patients — for transfusion to 
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contact exposure to COVID-19, but have not yet manifested symp-
toms. Per the US CDC, close contact exposure refers to being 
within approximately 6 feet (2 meters) of a patient with COVID-19 
for a prolonged period of time (without personal protective equip-
ment [PPE]). Close contact may occur while caring for, living 
with, visiting, or sharing a healthcare waiting area or room with a 
COVID-19 case or having direct contact with infectious secretions 
of a COVID-19–infected individual (e.g., being coughed on) with-
out PPE. If found to be safe and effective, postexposure prophy-
laxis would offer an intervention for vulnerable populations (e.g., 
health care workers, immunocompromised patients, individuals 
with cardiovascular and respiratory disease, nursing home resi-
dents) following exposure. Prevention would confer direct clini-
cal benefit for those at risk. Moreover, societal benefits would be 
wide ranging, including the protection of frontline workers in the 
COVID-19 pandemic.
The second trial will evaluate whether human anti–SARS–
CoV-2 plasma can help patients initially presenting with mild 
disease. The target population would comprise symptomatic indi-
viduals with confirmed SARS–CoV-2. The endpoints would be 
resolution of symptoms, prevention of hypoxemia on room air, 
or progression to severe disease, reflecting an interest in averting 
complications (and required hospitalization).
Third, the effect of human anti–SARS–CoV-2 plasma for mod-
erately ill patients would be studied. The target population is hospi-
talized patients with COVID-19 who manifest symptoms — albeit 
not of sufficient acuity to warrant ICU admission (and specifically 
mechanical ventilation). Staving off progression to critical illness 
could avoid overburdening of critical care resources currently in 
shortage, such as mechanical ventilators.
A fourth trial will evaluate human anti–SARS–CoV-2 plasma 
treatment as a rescue intervention in patients who require mechan-
ical ventilation due to COVID-19. This target group is important; 
however, it is also a group for which data are most difficult to inter-
pret, given the likely presence of confounding variables, including 
other putative therapies for COVID-19.
Finally, a fifth trial will examine safety and pharmacokinetics 
convalescent plasma in high-risk pediatric patients. Children of all 
ages are susceptible to COVID-19 infection; while comparatively 
rare, severe disease and even deaths have been described in chil-
dren (32), underscoring the need to address risk to children.
Complementing these five trials, studies are being designed to 
collect and mine data from emergency (i.e., compassionate) use of 
convalescent plasma or expanded access treatment.
Potential risks
Human plasma transfusion is a routine, daily event in modern 
hospitals. Human anti–SARS–CoV-2 plasma differs from standard 
plasma only by virtue of the presence of antibodies against SARS–
CoV-2. Donors will satisfy all criteria for blood donation based 
upon federal and state regulations for volunteer donor eligibility, 
and blood will be collected in FDA licensed blood centers.
Therefore, the risks to transfusion recipients are likely to be no 
different from those of standard plasma. Risk of transfusion-trans-
missible infection is very low in the US and other high-income 
countries. Typically cited estimates are less than one infection per 
two million donations for HIV, hepatitis B, and hepatitis C virus-
es (33). There are also noninfectious hazards of transfusion, such 
as allergic transfusion reactions, transfusion-associated circulato-
ry overload (TACO), and TRALI (34). While the risk of TRALI is 
generally less than one for every 5,000 transfused units, TRALI is 
of particular concern in severe COVID-19, given potential priming 
of the pulmonary endothelium. However, routine donor screening 
includes HLA antibody screening of female donors with a history 
of pregnancy to mitigate risk of TRALI (35). Of note, risk factors for 
TACO (e.g., cardiorespiratory disease, advanced age, renal impair-
ment, etc.) are shared by those at risk of COVID-19, underscoring 
the need for careful attention to fluid volume management.
Specific risks pertaining to human anti–SARS–CoV-2 plas-
ma include transfusion-transmitted SARS–CoV-2. This is largely 
theoretical, since the recipient is already infected and there has 
never been a report of transmission of a respiratory virus by blood 
transfusion. There is no donor screening in effect for common 
respiratory viruses, such as influenza, respiratory syncytial virus, 
and parainfluenza. SARS–CoV-2 is not considered to be a relevant 
transfusion-transmitted infection, and only 1% of symptomatic 
patients have been reported as having detectable SARS–CoV-2 
RNA in their blood (36, 37). In Wuhan, 2430 blood donations 
were screened in real time (January 25 to March 4, 2020): a sin-
gle (0.04%) — asymptomatic — donor was found to be positive for 
SARS–CoV-2 RNA (38). A second (0.02%) asymptomatic, SARS–
CoV-2 RNA–positive donor was identified on retrospective screen-
ing of 4995 donations (December 21 to January 22, 2020), and an 
additional two donors were identified as being RNA-emic through 
follow-up of donors who had developed fever subsequent to their 
donations. Nevertheless, donors will still need to wait 14 days fol-
lowing resolution of their symptoms to be eligible to donate.
There is also the theoretical possibility of antibody-dependent 
enhancement (ADE) following transfusion of human anti–SARS–
CoV-2 plasma. ADE refers to a process whereby antibodies that 
developed during a prior infection exacerbate clinical severity as a 
consequence of infection with a different viral serotype. This phe-
nomenon is well known for some viruses, notably Dengue virus 
(39). The largely theoretical risk of ADE in COVID-19 would be 
attributable to antibodies potentiating infection upon exposure to 
other strains of coronavirus; this mechanism has been offered as a 
possible reason for the geographic variation in disease severity (40). 
Concerns about coronavirus-ADE stem primarily from in vitro stud-
ies using mAbs, whose relevance is uncertain to the polyclonal anti-
body composition found in convalescent plasma (41). In this regard, 
mAbs have been shown to have very different properties when act-
ing as single molecules rather than in combination with other mAbs 
(42). Nonetheless, although ADE is unlikely to be relevant to the 
proposed use of convalescent plasma in prevention and treatment 
of a disease with the same virus, caution is warranted. Somewhat 
reassuring is the apparent absence of ADE reports with the use of 
convalescent plasma for SARS, MERS, or COVID-19.
For completion, it is unknown to what extent convales-
cent plasma might blunt the development of a natural immune 
response, especially when administered for prophylaxis.
Risk benefit analysis
In Figure 2, we constructed a stochastic age–specific suscep-
tible-exposed-infected-removed (SEIR) model of COVID-19 
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transmission reflective of the demography of Baltimore, Mary-
land, USA, to estimate the daily number of asymptomatic and 
symptomatic cases per day (43). Age-specific mixing was estimat-
ed using the POLYMOD data set for the United Kingdom obtained 
from the socialmxr R package (https://cran.r-project.org/
web/packages/socialmixr/socialmixr.pdf). The symptomatic- 
to-asymptomatic ratio was set to 80%/20% (44). Age-specific 
mortality rates were calculated using the age-specific case fatal-
ity ratio from the CDC (45). Age-specific severity rates 
were estimated using the National Center for Health 
Statistics on hypertension, diabetes, and cancer, where 
we assumed that the percentage of incident cases that 
become severe was roughly the same as the average per-
centage of individuals who have any of the above comor-
bidities. Transmission parameters were extracted from 
the literature to reflect both a moderate (R0 = 2.2) and 
high (R0 = 2.5) transmission setting (https://github.com/
midas-network/COVID-19/blob/master/parameter_ 
estimates/2019_novel_coronavirus/estimates.csv) (46). 
Multiple stochastic simulations were run (n = 500), with 
the 95% quantile and average provided. We considered 
incident cases for individuals between 20 and 74 to reflect 
the age range of healthcare workers. Healthcare workers 
may have a higher than population average contact rate 
with infected individuals; however, given uncertainties 
in this value, we adopted a conservative approach and 
assumed that mixing for healthcare workers was reflec-
tive of the general population without the deployment of 
any nonpharmaceutical interventions. Given uncertain-
ties in the effectiveness of the intervention, we assumed 
25%, 50%, or 75% effectiveness. We then calculated the 
breakpoint where the fatality ratio would need to be high-
er than this value for the treatment to be worse than the 
fatality ratio from the disease.
The model highlights overwhelming benefit from pro-
phylaxis or treatment with convalescent plasma even when 
conservative (e.g., 25%) estimates of efficacy are modeled. 
For example, the proposed clinical trial was designed with 
a projected attack rate of 20% (10.5%–35%) (47, 48); a high 
proportion of those who are infected will go on to severe 
disease, including death (~1%–4%) (2). In contrast, a total 
of 41 transfusion-associated fatalities (1 in 414,634 blood 
products) were reported to the FDA in 2015 (49). In short, 
blood transfusion in the US and other high-income coun-
tries is safe, and the associated risks are dwarfed by COVID-19–
associated morbidity and mortality.
Conclusion
The risks of COVID-19 infection are profound (50, 51). Human 
plasma from recovered COVID-19 patients is projected to be a 
safe and potentially effective therapy for treatment and postex-
posure prophylaxis alike. Substantial evidence of benefit with 
Figure 2. Mortality risk with SARS–CoV-2 convalescent plasma 
versus control by age, reproductive number, projected efficacy of 
intervention, and time. Fatalities from SARS-CoV-2 were estimat-
ed by age groups assuming moderate and high R0 scenarios over 
100 (d = 100) or 365 (d = 365) days. We calculated the number of 
averted deaths from treatment per 1,000 individuals for a range of 
treatment efficacy: (A) 25%, (B) 50%, and (C) 75%. We estimated 
these values using simulated incidence values from multiple runs 
of the transmission model. Results are shown for the mean (shown 
as a point) and 95% quantile. The estimated probability of death 
from a plasma transfusion was conservatively set at 41/3.6 million 
(solid black vertical line) (49).
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prior use for viral infections offers strong precedent for such an 
approach. However, it is critically important to perform well- 
controlled clinical trials to confirm efficacy, thereby informing 
rational evidence-based decision making.
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